PROSTATE FLOW (ORIGINAL)

Description

PROSTATE FLOW Normalize Size Reduce Infections

PROSTATE FLOW Reduce Prostate Urine Blockage Relieve Infection with Antipathogenics … Nutriodine, AllicinMED, NutruSilver, NutriDefense, NutrImmune 26 Y, and Power C Plus, and Take to Improve Motor Neural Control of Detrusor Muscles with Swedish Flower Pollen one to two tabs four times per day and Bladder UP one to two softgels twice per day.

Clinical Applications

• Supports Healthy Lower Urinary Tract (LUT) Function in Men*
• Supports Normal Urinary Flow and Nocturnal Frequency*
• Supports Healthy Prostate-Related Hormone Metabolism*
• Supports Prostate Health*

Description:

Prostate FLOW supports normal male lower urinary tract function and prostate health. Clinically meaningful levels of key ingredients target urinary flow and frequency as well as prostate-related hormone metabolism. This formula features FLOWENS^®—a full-spectrum cranberry powder optimized for men’s health—combined with beta-sitosterol, pyridoxal 5’-phosphate, TRAACS^® zinc bisglycinate chelate, and highly concentrated, standardized extracts of saw palmetto and pygeum.*

DIRECTIONS: Take one to two softgels daily, or use as directed by your healthcare professional. Consult your healthcare practitioner prior to use. Individuals taking medication should discuss potential interactions with their healthcare practitioner.

Serving Size: 2 Softgels
Servings Per Container: 60

** Daily Value not established.

Prostate Flow is a specialized formula designed for men to support male urinary flow, hormone metabolism, and overall prostate health. It contains a variety of synergistic, standardized herbs in addition to pumpkin
seed oil, vitamin B6, and zinc. Saw palmetto berry (Serenoa repens), widely studied and used in Europe, is present as a highly concentrated, standardized extract.*

Saw Palmetto Berry Extract (Serenoa repens), widely studied and used in Europe to support male urinary flow,[1] is standardized in this formula to contain 85-95% free fatty acids and sterols. The extract inhibits 5 alphareductase[
2] as well as DHT binding to androgen receptors,[3] has anti-estrogenic activity,[4] reduces prolactininduced
prostate enlargement[5] and IGF-1-induced prostate growth,[6] has anti-inflammatory activity,[7] and generally reduces edema.*[8]

Pygeum Africanum Bark Extract (Pygeum africanum), used for approximately 300 years, blocks androgen precursors, reduces prolactin levels, and has a decongesting, or anti-edema, effect. In animal models, Pygeum
modulates bladder hypercontractility. The bark extract increases prostatic secretions and improves seminal fluid composition.[9] In 2007, a critical review of this plant’s efficacy examined a detailed series of in vitro and in vivo studies on prostate growth and bladder function. Researchers identified molecular targets of Pygeum africanum extract affecting both growth factor-mediated prostate growth and specific parameters of bladder function.*[10]

Pumpkin Seed Oil Extract (Cucurbita pepo) is naturally rich in phytosterols, antioxidants, and unsaturated fatty acids (55% linoleic acid). A randomized, controlled, double-blind, three-month study (n=53) reported significant
improvement in urinary flow, urination time, residual urine, and urinary frequency without any adverse effects.*[11]
Uva-Ursi Extract (Arctostaphylos uva-ursi), derived from the Uva-Ursi leaf, contains 10% of the glycoside, arbutin, beneficial for its anti-microbial and diuretic properties.*[12,13]

Zinc inhibits 5a reductase, the enzyme that converts testosterone to its more potent form, dihydro-testosterone, believed to be most responsible for proliferative changes to the prostate.*[14]

All NutriMedical Formulas Meet or Exceed cGMP Quality Standards

*

References

1. Vidlar A, Student V Jr, Vostalova J, et al. Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study. World J Urol. 2016 Mar;34(3):419-24. [PMID: 26049866]

2. Vasileiou I, Katsargyris A, Theocharis S, et al. Current clinical status on the preventive effects of cranberry consumption against urinary tract infections. Nutr Res. 2013 Aug;33(8):595-607. [PMID: 23890348]

3. Sun J, Marais JP, Khoo C, et al. Cranberry (Vaccinium macrocarpon) oligosaccharides decrease biofilm formation by uropathogenic Escherichia coli. J Funct Foods. 2015 Aug;17:235-42. [PMID: 26613004]

4. Blumberg JB, Camesano TA, Cassidy A, et al. Cranberries and their bioactive constituents in human health. Adv Nutr. 2013 Nov 6;4(6):618-32. [PMID: 24228191]

5. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998 Nov 11;280(18):1604-09. Erratum in: JAMA 1999 Feb 10;281(6):515. [PMID: 9820264]

6. Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(3):CD001423. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001423. [PMID: 12137626]

7. Saw palmetto: clinical overview. In: Blumenthal M, Goldberg A, Kunz T, Dinda K, eds. The ABC Clinical Guide to Herbs. Austin, TX: American Botanical Council; 2003:309-319. http://abc.herbalgram.org/site/DocServer/Saw_Palmetto.pdf?docID=167. Accessed May 24, 2016.

8. Mantovani F. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol Nefrol. 2010 Dec;62(4):335-40. [PMID: 20944533]

9. Iii Colado-Velázquez J, Mailloux-Salinas P, Medina-Contreras J, et al. Effect of serenoa repens on oxidative stress, inflammatory and growth factors in obese wistar rats with benign prostatic hyperplasia. Phytother Res. 2015 Oct;29

(10):1525-31. [PMID: 26104840] 10. Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012 Dec 12;12:CD001423. [PMID: 23235581]

11. Marks LS, Hess, DL, Dorey FJ, et al. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology. 2001 May;57(5):999-1005. [PMID: 11337315]

12. Suzuki M, Ito Y, Fujino T, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009 Mar;30(3):227-81. [PMID: 19262550]

13. Saw Palmetto. Somerville, MA: Natural Medicines; 2016. https://naturalmedicines. therapeuticresearch.com/databases/food,-herbs-supplements/professional. aspx?productid=971. Accessed May 24, 2016.

14. Di Silverio F, D’Armeo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol. 1992;21(4):309-14. [PMID: 1281103]

15. Wadsworth TL, Carroll JM, Mallinson RA, et al. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology. 2004 Jul;145(7):3205-14. [PMID: 15033918]

16. Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res. 2000 Jun;28(3):201-09. [PMID: 10929430]

17. Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin. 1998;14(3):127- 39. [PMID: 9787978]

18. Pygeum Africanum. Somerville, MA: Natural Medicines; 2016. https:// naturalmedicines.therapeuticresearch.com/databases/food,-herbssupplements/professional.aspx?productid=388. Accessed May 24, 2016.

19. Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med. 2000 Dec 1;109(8):654-64. [PMID: 11099686]

20. Quiles MT, Arbós MA, Fraga A, et al. Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Prostate. 2010 Jul 1;70(10):1044-53. [PMID: 20503393]

21. Wilt T, Ishani A, MacDonald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044. [PMID: 11869585]

22. Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol study group. Lancet. 1995 Jun 17;345(8964):1529- 32. [PMID: 7540705]

23. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000 May;85(7):842-46. [PMID: 10792163]

24. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol. 1997 Sep;80(3):427-32. [PMID: 9313662]

25. Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999 Jun;83(9):976-83. [PMID: 10368239]

26. Yan M, Song Y, Wong CP, et al. Zinc deficiency alters DNA damage response genes in normal human prostate epithelial cells. J Nutr. 2008 Apr;138(4):667- 73. [PMID: 18356318]

27. Costello LC, Franklin RB, Tan MT. A critical assessment of epidemiology studies regarding dietary/supplemental zinc and prostate cancer risk. Open Urol Nephrol J. 2008;1. [PMID: 24204440]

28. Kasperzyk JL, Fall K, Mucci LA, et al. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr. 2009 Sep;90(3):561-69. [PMID: 19571228] Additional references available upon request.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.